Home Ingredients Levagen+® (PEA — Palmitoylethanolamide — Gencor)
Anti-InflammatoryCognitiveSleep Health

Levagen+® (PEA — Palmitoylethanolamide — Gencor)

Evidence Level
Strong
3 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

Levagen+® is the branded bioavailable palmitoylethanolamide (PEA) from Gencor (Austin, TX) — addressing the major issue with standard PEA: poor bioavailability of the hydrophobic compound. Levagen+® combines Gencor's PEA with LipiSperse® dispersion technology developed by Pharmako Biotechnologies (Australia, Gencor's sister/partner company) to enhance water dispersibility and bioavailability. A published pharmacokinetic study documented 1.75x absorption increase over standard PEA — meaningful but more modest than typical 'enhanced bioavailability' marketing implies. Clinical trials specifically using Levagen+® document benefits in pain, inflammation, sleep, and cognitive applications. The enhanced absorption may enable somewhat lower effective doses than standard PEA protocols, though the 1.75x absorption advantage doesn't translate to a proportional dose reduction. The honest framing: Levagen+® offers a documented bioavailability advantage over standard PEA through measured absorption-enhancing technology; the brand premium reflects this measurable improvement plus quality control; for users specifically seeking bioavailable PEA, Levagen+® provides clinically validated formulation.

Studied Dose 300-600 mg/day; sleep 350 mg before bed; pain 300 mg twice daily.
Active Compound Palmitoylethanolamide (PEA) with LipiSperse® dispersion technology (1.75× absorption vs standard PEA).

Benefits

Enhanced bioavailability over standard PEA

Levagen+® combines Gencor's PEA with LipiSperse® dispersion technology from Pharmako Biotechnologies. A published pharmacokinetic study documented 1.75x increased plasma PEA concentration vs standard PEA — meaningful but more modest than what 'enhanced bioavailability' marketing language sometimes implies.

Supported by Trial 2, Trial 1

Pain reduction at lower doses

Clinical trials using Levagen+® document pain reduction at 300-600 mg/day. While typical PEA pain protocols use 1,200 mg/day, the 1.75x bioavailability advantage doesn't translate to a 4x dose reduction — the lower effective doses in clinical trials may also reflect study design choices and different patient populations.

Supported by Trial 1

Sleep quality improvement

Levagen+® clinical trials specifically document sleep quality improvements when taken before bedtime. The sleep application is well-suited to the enhanced bioavailability format and represents an expanding evidence area for PEA.

Supported by Trial 2

Cognitive function support

Emerging Levagen+® research targets cognitive function support through PEA's anti-neuroinflammatory effects. Effect sizes are modest; useful as cognitive support adjunct rather than primary nootropic.

Supported by Trial 3

Anti-inflammatory effects

Like standard PEA, Levagen+® modulates PPAR-alpha and reduces inflammatory cytokines. The mechanism is preserved with enhanced absorption supporting more reliable clinical effects.

Supported by Trial 2, Trial 3

Consumer-friendly dose format

Lower effective doses (300-600 mg) enable consumer-friendly capsule formats versus larger PEA protocols requiring multiple capsules at higher doses. Practical advantage for adherence.

Supported by Trial 1

Mechanism of action

1

LipiSperse® dispersion technology

LipiSperse® is developed and owned by Pharmako Biotechnologies (Australia), a partner/sister company of Gencor. The technology addresses PEA's hydrophobic nature through water-dispersible delivery. Documented 1.75x absorption increase in published pharmacokinetic study.

2

PPAR-alpha activation

Levagen+® PEA activates PPAR-alpha nuclear receptors, modulating inflammation and lipid metabolism. Mechanism preserved with enhanced absorption.

3

Endocannabinoid-like signaling

PEA modulates the endocannabinoid system indirectly through 'entourage effects' — enhancing anandamide and other endogenous cannabinoid-like compounds. Mechanism contributes to pain, sleep, and inflammatory effects.

Clinical trials

1
Pain reduction at lower doses

Levagen+® clinical trials document pain reduction at 300-600 mg/day — substantially lower than typical PEA pain protocols.

Clinical population described in trial publication.

Levagen+® clinical trials document pain reduction at 300-600 mg/day — substantially lower than typical PEA pain protocols. The dose advantage validates the bioavailability technology.

2
Sleep quality trials

Levagen+® clinical trials specifically target sleep quality applications with documented improvements.

Clinical population described in trial publication.

Levagen+® clinical trials specifically target sleep quality applications with documented improvements. The sleep application is well-suited to the enhanced bioavailability format.

3
Cognitive and inflammation studies

Emerging clinical research targets cognitive function and inflammatory marker effects.

Clinical population described in trial publication.

Emerging clinical research targets cognitive function and inflammatory marker effects. Reflects expanding research investment in the bioavailable PEA format.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at standard doses.
Excellent safety profile inherited from PEA's long European medical food history.
Mild GI discomfort possible at higher doses.
No significant adverse events documented in clinical trial use.
Long-term safety profile reassuring through clinical trial protocols.
Pregnant women should consult healthcare providers.

Important Drug interactions

Generally minimal drug interactions documented.
Theoretical caution with anticoagulants — possible mild effects through inflammatory modulation.
No significant interactions with common pain medications — PEA is often used adjunctively.
Safe combinations with most cardiovascular, metabolic, and psychiatric medications.
Consult healthcare providers when combining with prescription medications for pain conditions.

More Anti-Inflammatory Ingredients

Anti-Inflammatory
Meriva® (Curcumin Phytosome — Indena)
Meriva® is a curcumin phytosome® formulation developed by Indena (Italy) — using Indena's…
Anti-Inflammatory
HydroCurc® (Highly Bioavailable Curcumin)
HydroCurc® is a highly bioavailable curcumin extract developed by Saanroo (formerly Gencor…
Anti-Inflammatory
TurmiPure Gold® (Bioavailable Turmeric — Naturex)
TurmiPure Gold® is a high-bioavailability turmeric extract developed by Naturex (now Givau…
Anti-Inflammatory
BCM-95® / Curcugreen® (Bioavailable Standardized Curcumin)
BCM-95® — now rebranded as Curcugreen® — is a standardized turmeric extract developed by A…

Explore Other Ingredients

Cognitive
L-Theanine
L-Theanine, an amino acid primarily found in green tea (Camellia sinensis), is commonly su…
Cognitive
Suntheanine®
Suntheanine® is a patented, 100% pure L-isomer theanine produced via an enzymatic process…
Sleep Health
Valerian Root
Valerian root is a traditional calming herb used for occasional sleeplessness and relaxati…

Frequently asked questions about Levagen+® (PEA — Palmitoylethanolamide — Gencor)

What is Levagen+?

Levagen+® is the branded bioavailable palmitoylethanolamide (PEA) from Gencor (Austin, TX) — addressing the major issue with standard PEA: poor bioavailability of the hydrophobic compound.

What is Levagen+ used for?

Levagen+ is researched primarily for Anti-Inflammatory, Cognitive, and Sleep Health. Levagen+® combines Gencor's PEA with LipiSperse® dispersion technology from Pharmako Biotechnologies. A published pharmacokinetic study documented 1.

What is the recommended dosage of Levagen+?

The clinically studied dose is 300-600 mg/day; sleep 350 mg before bed; pain 300 mg twice daily. Always follow the product label and check with a healthcare provider for personal advice.

Is Levagen+ safe, and does it have side effects?

For most healthy adults, Levagen+ is well tolerated at studied doses. Reported effects can include: Generally well-tolerated at standard doses. Excellent safety profile inherited from PEA's long European medical food history. It may also interact with some medications. Levagen+ is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Levagen+ interact with any medications?

Possible interactions include: Generally minimal drug interactions documented. Theoretical caution with anticoagulants — possible mild effects through inflammatory modulation. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Levagen+?

NutraSmarts rates the evidence for Levagen+ as Strong (4 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Mallard A, Briskey D, Richards A, Mills D, Rao A. The Effect of Orally Dosed Levagen+ (palmitoylethanolamide) on Exercise Recovery in Healthy Males-A Double-Blind, Randomized, Placebo-Controlled Study. Nutrients. 2020;12(3):596. doi: 10.3390/nu12030596.PubMedUsed to support: Brand-specific Levagen+ RCT (n=28 men, industry/Gencor-linked authors): liquid Levagen+ lowered post-exercise myoglobin and blood lactate after damaging leg-press exercise, supporting the exercise-recovery/muscle-damage claim, though muscle soreness itself was not significantly reduced.
  2. Rao A, Ebelt P, Mallard A, Briskey D. Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study. Sleep Sci Pract. 2021;5(1):12. doi: 10.1186/s41606-021-00065-3.PubMedUsed to support: Brand-specific Levagen+ RCT (n=103, 350 mg/day, 8 weeks; Gencor-funded, same Briskey/Rao group): PEA shortened sleep-onset latency and improved cognition on waking, but results were mixed - actigraphy/diary sleep quantity and quality did not differ from placebo.
  3. Fessler SN, Liu L, Chang Y, Yip T, Johnston CS. Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial. J Nutr. 2022;152(10):2218-2226. doi: 10.1093/jn/nxac154.PubMedUsed to support: Brand-specific Levagen+ RCT (600 mg twice daily, 4 weeks; explicitly Levagen+, funded by Gencor Pacific): PEA modestly reduced some inflammatory markers (soluble P-selectin, IL-1beta, IL-2) but had no effect on IL-6, CRP, or ferritin, giving mixed support for an anti-inflammatory claim.
  4. Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019;27(3):475-485. doi: 10.1007/s10787-019-00582-9.PubMedUsed to support: RCT (n=111) at the exact Levagen doses (300 and 600 mg/day, 8 weeks) from the same Gencor/Steels group: both PEA doses significantly reduced total WOMAC scores and pain versus placebo, supporting the knee-discomfort/joint claim, but the published abstract reports generic 'PEA' not the Levagen brand name, and it is industry-funded.